英夫利昔单抗治疗克罗恩病的有效性:一项随访15个月的多中心回顾性研究结果

作     者：Poupardin C. Lémann M. Gendre J.-P. B .Coffin 张诗峰(译) 李文彬(校) 

作者机构：不详 Service d' Hépato Gastro-Entérologie Hopital Louis Mourier 178 rue des Renouillers 92700 Colombes 

出 版 物：《世界核心医学期刊文摘（胃肠病学分册）》 (Core Journals in Gastroenterology)

年 卷 期：2006年第2卷第9期

页      面：31-32页

学科分类：1002[医学-临床医学] 1010[医学-医学技术（可授医学、理学学位）] 100215[医学-康复医学与理疗学] 10[医学] 

主　　题：单抗治疗 回顾性分析 克罗恩病 随访期 多中心 有效性 总体反应率 肛门周围疾病 

摘      要：Objectives-To evaluate prescription practices and response to infliximab treatment for Crohn’s disease(CD).Patients and methods-The files of CD patients treated with at least one infusion of infliximab treated in gastroenterology units belonging to university teaching hospitals of the Parisian hospitals group(Assistance Publique-Hpitaux de Paris(AP-HP))during the year 2000 were analyzed ***-One hundred and thirty-seven patients(36.0 ±12.7 years,92 females)from 12 centers were *** for treatment was fistulae or perianal disease in 39%of patients,active Crohn’s disease in 45and mixed conditions in 16%.Mean follow-up was 15.2 ±7.2 *** overall response rate was 85%.No predictive factor of sustained remission could be *** mean time to relapse was to 3.9 ±3.1 ***-eight patients were on maintenance therapy at the end of the follow-up;37%exhibiting progressive lost of response to *** therapy was added to infliximab in 78%of cases but response to infliximab was not modified by addition of immunosuppressive *** events,most frequently minor,were noted in 23%of the ***-This retrospective study confirms the efficacy and safety of infliximab in CD.